Creative medical technology holdings develops allostem™ clinical cell line

Phoenix , oct. 20, 2022 /prnewswire/ -- creative medical technology holdings, inc. (nasdaq: celz), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, neurology, and orthopedics, announced today that through predominantly internal and collaborative development, it has produced an allogenic cell line called allostem™, which includes a master cell bank and a drug master file which shall be submitted for fda registration. "the importance of the company creating and developing such assets, as opposed to licensing agreements with third parties, provides further de-risking of an important component to many of our programs, including, but not limited to, the immcelz® immunotherapy platform for multiple diseases, ovastem® for premature ovarian failure, allostem™ for type 1 diabetes, stemspine® for lower back pain, and ipscelz ™ inducible pluripotent stem cell program in ongoing development with greenstone biosciences," said timothy warbington, ceo.
CELZ Ratings Summary
CELZ Quant Ranking